<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687271</url>
  </required_header>
  <id_info>
    <org_study_id>6213-006</org_study_id>
    <secondary_id>2007_514</secondary_id>
    <secondary_id>2007-003684-41</secondary_id>
    <secondary_id>MK-6314-006</secondary_id>
    <nct_id>NCT00687271</nct_id>
  </id_info>
  <brief_title>A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy, and Tolerability of MK-6213 Co-Administered With Atorvastatin in Patients With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and effectiveness of MK-6213 as compared to
      MK-6213/Atorvastatin in participants 18 to 75 years) with high cholesterol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2008</start_date>
  <completion_date type="Actual">January 8, 2009</completion_date>
  <primary_completion_date type="Actual">January 8, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline (predose) and Week 4</time_frame>
    <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine LDL-C levels. LDL-C was calculated using the Friedewald equation. If triglycerides (TG) exceeded 400 mg/dL (4.6 mmol/L), LDL-C was determined by reflex beta-quantitation method. The percentage change from baseline at Week 4 was summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience at Least 1 Adverse Event (AE)</measure>
    <time_frame>Up to 14 days post last dose of study drug (up to 6 weeks)</time_frame>
    <description>An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Had Study Drug Discontinued Due to an AE</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who had study drug discontinued due to an AE was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)</measure>
    <time_frame>Baseline (predose) and Week 4</time_frame>
    <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine non-HDL-C levels. The percentage change from baseline at Week 4 was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Apolipoprotein B (ApoB)</measure>
    <time_frame>Baseline (predose) and Week 4</time_frame>
    <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine ApoB levels. The percentage change from baseline at Week 4 was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Total Cholesterol (TC)</measure>
    <time_frame>Baseline (predose) and Week 4</time_frame>
    <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine TC levels. The percentage change from baseline at Week 4 was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in HDL-C</measure>
    <time_frame>Baseline (predose) and Week 4</time_frame>
    <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine HDL-C levels. The percentage change from baseline at Week 4 was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in TG</measure>
    <time_frame>Baseline (predose) and Week 4</time_frame>
    <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine TG levels. The percentage change from baseline at Week 4 was summarized.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">334</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>MK-6213 160 mg + Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-6213 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-6213</intervention_name>
    <description>MK-6213 160 mg for 4 weeks.</description>
    <arm_group_label>MK-6213 160 mg</arm_group_label>
    <arm_group_label>MK-6213 160 mg + Atorvastatin 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin calcium</intervention_name>
    <description>atorvastatin calcium 20mg for 4 weeks.</description>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_label>MK-6213 160 mg + Atorvastatin 20 mg</arm_group_label>
    <other_name>atorvastatin</other_name>
    <other_name>LIPITOR Â®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for MK-6312 160 mg</intervention_name>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Atorvastatin 20 mg</intervention_name>
    <arm_group_label>MK-6213 160 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 75 years of age at the time of the study with high cholesterol

          -  Can have diabetes mellitus but is not currently on lipid lowering therapy

          -  Have a stable weight for &gt;6 weeks

        Exclusion Criteria:

          -  Has significant cardiovascular (heart), renal (kidney), neurologic (nervous system),
             respiratory (lung), hepatic (liver) or metabolic disease

          -  history of mental instability or drug/alcohol abuse within the past 5 years

          -  Pregnant or nursing; human immunodeficiency virus (HIV) positive; history of cancer
             within the past 5 years or participation in an investigational trial within the last
             30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Colombia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <results_first_submitted>October 2, 2018</results_first_submitted>
  <results_first_submitted_qc>October 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2018</results_first_posted>
  <last_update_submitted>January 11, 2019</last_update_submitted>
  <last_update_submitted_qc>January 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MK-6213 160 mg + Atorvastatin 20 mg</title>
          <description>1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin 20 mg</title>
          <description>1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>MK-6213 160 mg</title>
          <description>1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="96"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="96"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="91"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK-6213 160 mg + Atorvastatin 20 mg</title>
          <description>1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin 20 mg</title>
          <description>1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>MK-6213 160 mg</title>
          <description>1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
            <count group_id="B2" value="96"/>
            <count group_id="B3" value="96"/>
            <count group_id="B4" value="48"/>
            <count group_id="B5" value="334"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.9" spread="10.9"/>
                    <measurement group_id="B2" value="53.6" spread="10.2"/>
                    <measurement group_id="B3" value="56.2" spread="10.0"/>
                    <measurement group_id="B4" value="54.7" spread="10.7"/>
                    <measurement group_id="B5" value="54.3" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="178"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)</title>
        <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine LDL-C levels. LDL-C was calculated using the Friedewald equation. If triglycerides (TG) exceeded 400 mg/dL (4.6 mmol/L), LDL-C was determined by reflex beta-quantitation method. The percentage change from baseline at Week 4 was summarized.</description>
        <time_frame>Baseline (predose) and Week 4</time_frame>
        <population>All participants that received at least 1 dose of study drug, had baseline value for parameter and had data available for timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-6213 160 mg + Atorvastatin 20 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-6213 160 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)</title>
          <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine LDL-C levels. LDL-C was calculated using the Friedewald equation. If triglycerides (TG) exceeded 400 mg/dL (4.6 mmol/L), LDL-C was determined by reflex beta-quantitation method. The percentage change from baseline at Week 4 was summarized.</description>
          <population>All participants that received at least 1 dose of study drug, had baseline value for parameter and had data available for timepoint.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.7" lower_limit="-53.8" upper_limit="-47.5"/>
                    <measurement group_id="O2" value="-40.6" lower_limit="-43.8" upper_limit="-37.4"/>
                    <measurement group_id="O3" value="-13.3" lower_limit="-16.5" upper_limit="-0.1"/>
                    <measurement group_id="O4" value="4.6" lower_limit="0.2" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percentage Change</param_type>
            <param_value>-10.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.6</ci_lower_limit>
            <ci_upper_limit>-5.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percentage Change</param_type>
            <param_value>-17.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.4</ci_lower_limit>
            <ci_upper_limit>-12.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experience at Least 1 Adverse Event (AE)</title>
        <description>An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized</description>
        <time_frame>Up to 14 days post last dose of study drug (up to 6 weeks)</time_frame>
        <population>All participants that received at least 1 dose for study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-6213 160 mg + Atorvastatin 20 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-6213 160 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience at Least 1 Adverse Event (AE)</title>
          <description>An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized</description>
          <population>All participants that received at least 1 dose for study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0"/>
                    <measurement group_id="O2" value="37.9"/>
                    <measurement group_id="O3" value="29.2"/>
                    <measurement group_id="O4" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Had Study Drug Discontinued Due to an AE</title>
        <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who had study drug discontinued due to an AE was summarized.</description>
        <time_frame>up to 4 weeks</time_frame>
        <population>All participants that received at least 1 dose for study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-6213 160 mg + Atorvastatin 20 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-6213 160 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Had Study Drug Discontinued Due to an AE</title>
          <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who had study drug discontinued due to an AE was summarized.</description>
          <population>All participants that received at least 1 dose for study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="1.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)</title>
        <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine non-HDL-C levels. The percentage change from baseline at Week 4 was summarized.</description>
        <time_frame>Baseline (predose) and Week 4</time_frame>
        <population>All participants that received at least 1 dose of study drug, had baseline value for parameter and had data available for timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-6213 160 mg + Atorvastatin 20 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-6213 160 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)</title>
          <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine non-HDL-C levels. The percentage change from baseline at Week 4 was summarized.</description>
          <population>All participants that received at least 1 dose of study drug, had baseline value for parameter and had data available for timepoint.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.6" lower_limit="-49.5" upper_limit="-43.6"/>
                    <measurement group_id="O2" value="-38.0" lower_limit="-41.0" upper_limit="-35.0"/>
                    <measurement group_id="O3" value="-11.4" lower_limit="-14.3" upper_limit="-8.5"/>
                    <measurement group_id="O4" value="2.5" lower_limit="-1.6" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percentage Change</param_type>
            <param_value>-8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.7</ci_lower_limit>
            <ci_upper_limit>-4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Diffence in Percentage Change</param_type>
            <param_value>-13.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.9</ci_lower_limit>
            <ci_upper_limit>-8.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Apolipoprotein B (ApoB)</title>
        <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine ApoB levels. The percentage change from baseline at Week 4 was summarized.</description>
        <time_frame>Baseline (predose) and Week 4</time_frame>
        <population>All participants that received at least 1 dose of study drug, had baseline value for parameter and had data available for timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-6213 160 mg + Atorvastatin 20 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-6213 160 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Apolipoprotein B (ApoB)</title>
          <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine ApoB levels. The percentage change from baseline at Week 4 was summarized.</description>
          <population>All participants that received at least 1 dose of study drug, had baseline value for parameter and had data available for timepoint.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.4" lower_limit="-43.1" upper_limit="-37.7"/>
                    <measurement group_id="O2" value="-32.7" lower_limit="-35.4" upper_limit="-30.0"/>
                    <measurement group_id="O3" value="-8.8" lower_limit="-11.5" upper_limit="-6.1"/>
                    <measurement group_id="O4" value="3.5" lower_limit="-0.3" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percentage Change</param_type>
            <param_value>-7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.5</ci_lower_limit>
            <ci_upper_limit>-3.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percentage Change</param_type>
            <param_value>-12.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.8</ci_lower_limit>
            <ci_upper_limit>-7.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Total Cholesterol (TC)</title>
        <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine TC levels. The percentage change from baseline at Week 4 was summarized.</description>
        <time_frame>Baseline (predose) and Week 4</time_frame>
        <population>All participants that received at least 1 dose of study drug, had baseline value for parameter and had data available for timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-6213 160 mg + Atorvastatin 20 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-6213 160 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Total Cholesterol (TC)</title>
          <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine TC levels. The percentage change from baseline at Week 4 was summarized.</description>
          <population>All participants that received at least 1 dose of study drug, had baseline value for parameter and had data available for timepoint.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.1" lower_limit="-37.4" upper_limit="-32.7"/>
                    <measurement group_id="O2" value="-27.6" lower_limit="-30.0" upper_limit="-25.2"/>
                    <measurement group_id="O3" value="-8.5" lower_limit="-10.9" upper_limit="-6.2"/>
                    <measurement group_id="O4" value="2.5" lower_limit="-0.8" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percentage Change</param_type>
            <param_value>-7.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.8</ci_lower_limit>
            <ci_upper_limit>-4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percentage Change</param_type>
            <param_value>-11.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.1</ci_lower_limit>
            <ci_upper_limit>-7.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in HDL-C</title>
        <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine HDL-C levels. The percentage change from baseline at Week 4 was summarized.</description>
        <time_frame>Baseline (predose) and Week 4</time_frame>
        <population>All participants that received at least 1 dose of study drug, had baseline value for parameter and had data available for timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-6213 160 mg + Atorvastatin 20 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-6213 160 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in HDL-C</title>
          <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine HDL-C levels. The percentage change from baseline at Week 4 was summarized.</description>
          <population>All participants that received at least 1 dose of study drug, had baseline value for parameter and had data available for timepoint.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.9" upper_limit="6.8"/>
                    <measurement group_id="O2" value="6.2" lower_limit="3.2" upper_limit="9.2"/>
                    <measurement group_id="O3" value="1.4" lower_limit="-1.6" upper_limit="4.3"/>
                    <measurement group_id="O4" value="2.1" lower_limit="-2.1" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Dfferecne in Percentage Change</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percentage Change</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in TG</title>
        <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine TG levels. The percentage change from baseline at Week 4 was summarized.</description>
        <time_frame>Baseline (predose) and Week 4</time_frame>
        <population>All participants that received at least 1 dose of study drug, had baseline value for parameter and had data available for timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-6213 160 mg + Atorvastatin 20 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-6213 160 mg</title>
            <description>1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in TG</title>
          <description>Blood collected at baseline (predose) and after 4 weeks of treatment to determine TG levels. The percentage change from baseline at Week 4 was summarized.</description>
          <population>All participants that received at least 1 dose of study drug, had baseline value for parameter and had data available for timepoint.</population>
          <units>Percentage of Participants</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.2" lower_limit="-29.6" upper_limit="-18.9"/>
                    <measurement group_id="O2" value="-25.9" lower_limit="-32.1" upper_limit="-19.7"/>
                    <measurement group_id="O3" value="1.6" lower_limit="-6.9" upper_limit="10.1"/>
                    <measurement group_id="O4" value="-7.1" lower_limit="-17.2" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percentage Change</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.7</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percentage Change</param_type>
            <param_value>5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>16.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 2 weeks post last dose (up to 6 weeks total)</time_frame>
      <desc>Population included all participants that received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-6213 160 mg + Atorvastatin 20 mg</title>
          <description>1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin 20 mg</title>
          <description>1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>MK-6213 160 mg</title>
          <description>1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

